Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

265 trials

NCT06224309
Recruiting
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Not applicable · Canada · 1 site
Registry update: 1 Oct 2026
NCT06346912
Recruiting
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Early phase 1 · China · 1 site
Registry update: 14 May 2024
NCT06299540
Recruiting
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
Not applicable · France · 1 site
Registry update: 3 Nov 2026
NCT06506643
Recruiting
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Phase 1/2 · Ukraine · 2 sites
Registry update: 5 Aug 2026
NCT06508099
Recruiting
Vitamin A and D Supplementation in Allogeneic HCT
Phase 2 · Russia · 1 site
Registry update: 31 Jul 2024
NCT06378138
Recruiting
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Phase 2/3 · China · 53 sites
Registry update: 21 Nov 2025
NCT06762431
Recruiting
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
Phase 1/2 · Belarus · 1 site
Registry update: 13 Aug 2026
NCT06508775
Recruiting
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Phase 1/2 · Germany · 9 sites
Registry update: 9 Oct 2026
NCT05800210
Recruiting
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Phase 2 · United States · 1 site
Registry update: 4 Jun 2026
NCT06355583
Recruiting
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Phase 2 · United Kingdom · 8 sites
Registry update: 17 Apr 2025
NCT06539182
Recruiting
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Phase 2 · China · 14 sites
Registry update: 2 Jun 2026
NCT06333262
Recruiting
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Phase 2 · United States · 4 sites
Registry update: 21 Jan 2026
NCT05791409
Recruiting
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Phase 1/2 · Australia, Belgium, Germany, Denmark, Netherlands · 27 sites
Registry update: 5 Oct 2026
NCT06462365
Recruiting
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 · United States · 5 sites
Registry update: 15 Apr 2025
NCT06319456
Recruiting
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Phase 3 · Bulgaria, China, Czechia, Spain · 15 sites
Registry update: 28 Jul 2026
2022-501554-11-00
Recruiting
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY
Phase 2 · France · 27 sites
Registry update: 20 Aug 2026
NCT06191887
Recruiting
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Phase 1 · United States · 1 site
Registry update: 13 Feb 2026
NCT06355739
Recruiting
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
Not applicable · China · 2 sites
Registry update: 9 Apr 2024
NCT06043674
Recruiting
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Phase 2 · United States · 5 sites
Registry update: 21 Oct 2026
NCT06151730
Recruiting
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Not applicable · United States · 1 site
Registry update: 27 Feb 2026

Ordered by registry start date. Freshness and sponsorship never change the order.